Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Snyder

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Blood Cancer Journal|July 3, 2021
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomesIbrahim Aldoss, Raju Pillai, Dongyun Yang, et al.
Transfusion|August 24, 2007
Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantationShirong Wang, Auayporn Nademanee, Dajun Qian, et al.
American Journal of Hematology|July 2, 2019
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaIbrahim Aldoss, Dongyun Yang, Raju Pillai, et al.
Blood Advances|June 22, 2021
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplantMonzr M Al Malki, Ni-Chun Tsai, Joycelynne Palmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2020
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaAmandeep Salhotra, Dongyun Yang, Sally Mokhtari, et al.
American Journal of Hematology|July 7, 2020
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemiaIbrahim Aldoss, Jianying Zhang, Matthew Mei, et al.
Blood Advances|January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimenHaris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
Bone Marrow Transplantation|November 8, 2019
Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosisRohan Gupta, Faizi Jamal, Dongyun Yang, et al.
Transplantation and Cellular Therapy|March 30, 2021
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage TherapiesIbrahim Aldoss, Dongyun Yang, Monzr M Al Malki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2018
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell TransplantationMonzr M Al Malki, Nitya Nathwani, Dongyun Yang, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Blood Cancer Journal|July 3, 2021
Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomesIbrahim Aldoss, Raju Pillai, Dongyun Yang, et al.
Transfusion|August 24, 2007
Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantationShirong Wang, Auayporn Nademanee, Dajun Qian, et al.
American Journal of Hematology|July 2, 2019
Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemiaIbrahim Aldoss, Dongyun Yang, Raju Pillai, et al.
Blood Advances|June 22, 2021
Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplantMonzr M Al Malki, Ni-Chun Tsai, Joycelynne Palmer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 9, 2020
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaAmandeep Salhotra, Dongyun Yang, Sally Mokhtari, et al.
American Journal of Hematology|July 7, 2020
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemiaIbrahim Aldoss, Jianying Zhang, Matthew Mei, et al.
Blood Advances|January 10, 2019
MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimenHaris Ali, Ibrahim Aldoss, Dongyun Yang, et al.
Bone Marrow Transplantation|November 8, 2019
Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosisRohan Gupta, Faizi Jamal, Dongyun Yang, et al.
Transplantation and Cellular Therapy|March 30, 2021
Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage TherapiesIbrahim Aldoss, Dongyun Yang, Monzr M Al Malki, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2018
Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell TransplantationMonzr M Al Malki, Nitya Nathwani, Dongyun Yang, et al.
Pageof 9